Cell therapy and clinical operations
FDA’s Cell and Gene Therapy Potency Guidance and What It Means for Trial Teams
Read what FDA’s November 2026 final potency assurance guidance means for cell and gene therapy manufacturing, CAR-T site readiness, and CRA monitoring.
By Lampgen Clinical Research

3 min read · estimated
What the source reported
The FDA announced final guidance on potency assurance for cellular and gene therapy products on November 2, 2026, superseding its January 2011 potency testing guidance. Potency describes a product’s capacity to produce its intended biological effect. Evidence that a lot meets its potency criteria helps establish product quality. Whether patients benefit is a separate clinical question. [1, 2]
The guidance recommends using risk assessment to decide which materials to control, where to test during manufacturing, and which assays to use for lot release. For investigational products, the strategy should become more robust as clinical development advances. If manufacturing changes, potency assay data can help assess whether the product made before and after the change is comparable. [2]
The FDA also addresses therapies with very short shelf lives. In some circumstances a functional assay may take longer than the product can be held before release. The guidance describes how a sponsor can combine other controls and tests with post-release functional testing in a product-specific strategy, subject to applicable requirements. [2]
What this means for trial teams
The courier arrives on time. The patient is ready. The site has no release confirmation. What happens next? A sponsor’s chemistry, manufacturing, and controls (CMC) strategy informs the study’s product procedures. The site still needs a clear way to verify status, act on an exception, and tell the patient what happens to the visit.
Before activation, rehearse a disrupted dosing day. Confirm how pharmacy or the cell therapy unit receives release status, how staff verify receipt and handling against the study manual, and whom they contact when status is unclear or an excursion occurs. For an autologous CAR-T study, include a check of the records that link the collected cells to the participant throughout processing and administration. FDA discusses chain of identity in its separate CAR-T guidance. [3]
Define what the CRA should verify and escalate. A monitor can reconcile protocol-required product records with the dosing timeline, confirm that an exception reached the right team, and follow it through closure. Product release belongs to authorized manufacturing or quality personnel under the study procedures. Clinical decisions belong to the investigator.
Track the burden of a missed dose window. Product-related postponements can mean repeat travel, more time away from work, or a caregiver rearranging support. Tracking the reason for each delay and whether the participant was able to return can show where the process is making trial participation harder. Earlier alignment across manufacturing, quality and clinical operations can help teams reduce avoidable rework and interpret trial data when the product or process changes.
At Lampgen Clinical Research, we use practical scenarios when screening oncology CRAs for sponsors and CROs. We look for monitors who can explain which records they would verify, how they would escalate an exception, and how they would confirm that the follow-up was documented.